Drug: Epidermal growth factor receptor (EGFR)-targeted, doxorubicin-loaded EDV nanocells (EnGeneIC)
Status: Granted orphan drug designation for the treatment of glioblastoma multiforme
Significant Information:
- A nanoparticle drug platform designed to directly target and kill tumor cells with minimal toxicity, while stimulating the immune system’s natural antitumor response
- Intravenously injected EDV nanocells exit the leaky vascular system found within tumors and attach to cancer cells via a